Study of a Pandemic Influenza Vaccine
Phase 1
Completed
- Conditions
- Influenza
- Registration Number
- NCT00136331
- Lead Sponsor
- Seqirus
- Brief Summary
The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic. This study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in healthy adults.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
- Healthy adults
Exclusion Criteria
- History of Guillain-Barre syndrome or active neurological disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety and immunogenicity
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of H5N1 vaccine-induced immune responses in NCT00136331?
How does the H5N1 pandemic vaccine in NCT00136331 compare to standard seasonal influenza vaccines in immunogenicity?
What biomarkers correlate with safety and efficacy outcomes in NCT00136331 H5N1 vaccine trial?
What adverse events were observed in NCT00136331 and how were they managed in pandemic vaccine development?
What are the current status and efficacy of H5N1 vaccines developed by Seqirus compared to other manufacturers?
Trial Locations
- Locations (2)
CMAX, a division of IDT Australia
🇦🇺Adelaide, South Australia, Australia
Murdoch Childrens Research Institute
🇦🇺Melbourne, Victoria, Australia
CMAX, a division of IDT Australia🇦🇺Adelaide, South Australia, Australia